GlobeNewswire Inc.··Not SpecifiedIncyclix Bio Secures $5M Series B Extension to Advance CDK2 Inhibitor Trial
Incyclix Bio raises $5M from Hatteras Venture Partners for Phase 1/2 trial of INX-315, targeting therapy-resistant breast and ovarian cancers.
LLYbreast cancerclinical trial